Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.

EClinicalMedicine · 2022 · PMC9358426 · PMID 35958519

Europe PMC DOI

hedged sentence

0.0050

closest p · 0.1× alpha

0.0050

boldest claim

The sentences

did not reach statistical significancep =0.005actually significant

22 This difference did not reach statistical significance, 22 unlike results from our study, which showed a statistically significant effect of IV edaravone on survival (HR, 0.73; 95% CI, 0.59–0.91; p =0.005).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.